Evidence map›Paper›PMID 42420684›Full record

ArticleHormones (Athens, Greece)2026

Highly selective SGLT2 inhibitors suppress glucose uptake in alpha-TC1 cells, while glucagon secretion is not affected.

Licht Miyamoto, Suguru Nakayama, Honoka Endoh, Kano Fujiwara, Mana Hattori, Takashi Yasuoka, Masaki Imanishi, Yasumasa Ikeda, Koichiro Tsuchiya

Abstract read
PubMed Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Licht MiyamotoDepartment of Nutrition and Life Science, Laboratory of Physiology, Pharmacology and Food Science, Faculty of Health and Medical Sciences, Kanagawa Institute of Technology, Shimo-Ogino, Atsugi-Shi, Kanagawa, 1030243-0292, Japan. licht_corresp2011@yahoo.co.jp.ORCID http://orcid.org/0000-0003-2331-964X
Suguru NakayamaDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Honoka EndohDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Kano FujiwaraDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Mana HattoriDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Takashi YasuokaDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Masaki ImanishiDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.
Yasumasa IkedaDepartment of Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 3-18-15, Kuramoto-Cho, Tokushima, 770-8505, Japan.
Koichiro TsuchiyaDepartment of Medical Pharmacology, Institute of Biomedical Sciences, Graduate School of Tokushima University, 1-78-1, Sho-Machi, Tokushima, 770-8505, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe existence of sodium-glucose cotransporter 2 (SGLT2) in pancreatic alpha cells and its potential roles in glucagon secretion remain controversial despite its well-established function in renal glucose reabsorption. While some studies suggest SGLT2 presence and its involvement in glucagon regulation, others report no expression in alpha cells.

methodsTo clarify this dispute, we investigated the acute functional effects of the highly selective SGLT2 inhibitors dapagliflozin and empagliflozin on glucose uptake, intracellular ATP levels, and glucagon secretion in alpha-TC1 cells, a widely used model of glucagon-secreting cells in culture.

resultsThe SGLT2 inhibitors significantly suppressed basal glucose uptake in alpha-TC1 cells, suggesting the presence of functional SGLT2. However, the inhibitors did not affect glucagon secretion. Neither the SGLT2 inhibitors nor the more potent glucose transport inhibitor, cytochalasin B, altered intracellular ATP levels or glucagon secretion. In contrast, pharmacological inhibition of K/ATP channels increased glucagon secretion without affecting glucose uptake or ATP levels.

conclusionThese results suggest that while SGLT2 is functionally present at low levels and mediates basal glucose uptake in alpha-TC1 cells, its inhibition has insufficient influence on intracellular ATP levels, and therefore, glucagon secretion remains stable. Furthermore, our observations support predominant involvement of K/ATP channels in regulating glucagon secretion.

Indexed as

Alpha-TC1 cellsGlucagon secretionGlucose uptakePancreatic alpha cellsSGLT2 (sodium-glucose cotransporter 2)

Identifiers

PMID42420684

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.